Pharmaceutical Product Liability, Litigation Regimes, and the Propensity to Patent: An Empirical Firm-Level Investigation

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Technology sourcing: an empirical analysis using firm-level patent data∗

This paper examines whether UK firms that locate their R&D activity in the USA benefit more than other UK firms from knowledge spillovers originating from US R&D. Patent data provides a firm-level measure of the location of innovative activity, which enables the identification of knowledge spillovers associated with "technology sourcing". Our identification strategy helps to address various pro...

متن کامل

Pharmaceutical Product Liability

Product liability is one of the fastest growing and most economically significant applications of tort law. Product liability actions against pharmaceutical companies are among the most widely publicized classes of suits in the United States and Europe, prompting pharmaceutical companies to lobby vigorously for tort reform. (Nace et al., 1997). The liability burden on pharmaceutical companies h...

متن کامل

The Pharmaceutical Industry and Product Liability Exposures

In the broadest sense, the Pharmaceutical Industry comprises various different business models which cover all or only some parts of the pharmaceutical product life cycle. Traditionally, the pharmaceutical industry segment was constituted by research-based pharmaceutical companies which had an integrated business model from the research laboratory to distribution, meaning they developed, manufa...

متن کامل

The Economics of Commercial Success in Pharmaceutical Patent Litigation

Under the 1984 Hatch-Waxman Act, a generic drug manufacturer may seek FDA approval to enter a market before patents on the branded drug expire by claiming that the relevant patents are invalid or not infringed. Since the Act’s passage, the share of generic manufacturers’ Abbreviated New Drug Applications (ANDAs) that make such claims has been increasing substantially. The result has been an inc...

متن کامل

Incentives to Settle Under Joint and Several Liability: An Empirical Analysis of Superfund Litigation

Congress may soon restrict join t and several l iabi l i ty for c leanup of contaminated sites under Superfund. We explore whether this change would discourage settle­ ments and is therefore l ikely to increase the program ' s already high litigation costs per site. Recent theoretical research by Kornhauser and Revesz finds that joint and several l iab i l i ty may either encourage or discourag...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: SAGE Open

سال: 2021

ISSN: 2158-2440,2158-2440

DOI: 10.1177/21582440211009470